Bank of New York Mellon’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.6M Buy
377,402
+14,994
+4% +$720K ﹤0.01% 1711
2026
Q1
$18.7M Sell
362,408
-8,380
-2% -$427K ﹤0.01% 1577
2025
Q4
$18.4M Sell
370,788
-5,813
-2% -$283K ﹤0.01% 1586
2025
Q3
$18M Sell
376,601
-20,777
-5% -$837K ﹤0.01% 1600
2025
Q2
$12.5M Buy
397,378
+11,877
+3% +$381K ﹤0.01% 1774
2025
Q1
$12.6M Sell
385,501
-14,083
-4% -$499K ﹤0.01% 1741
2024
Q4
$14.4M Buy
399,584
+27,134
+7% +$955K ﹤0.01% 1735
2024
Q3
$11.6M Sell
372,450
-52,937
-12% -$1.65M ﹤0.01% 1849
2024
Q2
$11.4M Buy
425,387
+2,427
+0.6% +$70.3K ﹤0.01% 1894
2024
Q1
$14.4M Sell
422,960
-22,412
-5% -$667K ﹤0.01% 1757
2023
Q4
$12.9M Sell
445,372
-10,555
-2% -$280K ﹤0.01% 1834
2023
Q3
$12.6M Sell
455,927
-2,093
-0.5% -$63.7K ﹤0.01% 1806
2023
Q2
$13.8M Sell
458,020
-30,115
-6% -$1.05M ﹤0.01% 1772
2023
Q1
$17.7M Sell
488,135
-22,890
-4% -$880K ﹤0.01% 1613
2022
Q4
$18.2M Sell
511,025
-10,202
-2% -$355K ﹤0.01% 1587
2022
Q3
$17.6M Buy
521,227
+9,723
+2% +$316K ﹤0.01% 1569
2022
Q2
$14.8M Sell
511,504
-33,867
-6% -$970K ﹤0.01% 1709
2022
Q1
$17.6M Sell
545,371
-1,251
-0.2% -$38.4K ﹤0.01% 1744
2021
Q4
$15.9M Sell
546,622
-70,498
-11% -$2.14M ﹤0.01% 1855
2021
Q3
$16.5M Buy
617,120
+7,826
+1% +$210K ﹤0.01% 1830
2021
Q2
$18.8M Sell
609,294
-47,384
-7% -$1.45M ﹤0.01% 1776
2021
Q1
$17.2M Buy
656,678
+427
+0.1% +$11.9K ﹤0.01% 1788
2020
Q4
$16.5M Sell
656,251
-4,856
-0.7% -$105K ﹤0.01% 1738
2020
Q3
$13.8M Sell
661,107
-25,112
-4% -$570K ﹤0.01% 1683
2020
Q2
$16.3M Sell
686,219
-7,007
-1% -$155K ﹤0.01% 1570
2020
Q1
$12.5M Sell
693,226
-25,493
-4% -$536K ﹤0.01% 1566
2019
Q4
$17M Sell
718,719
-278,739
-28% -$6.77M ﹤0.01% 1662
2019
Q3
$27.4M Sell
997,458
-31,901
-3% -$945K 0.01% 1329
2019
Q2
$34.1M Sell
1,029,359
-11,080
-1% -$380K 0.01% 1214
2019
Q1
$36.5M Sell
1,040,439
-166,193
-14% -$6.18M 0.01% 1172
2018
Q4
$40.1M Sell
1,206,632
-49,329
-4% -$2.12M 0.01% 1034
2018
Q3
$63.2M Sell
1,255,961
-188,759
-13% -$9.32M 0.02% 858
2018
Q2
$86.5M Sell
1,444,720
-39,379
-3% -$2.04M 0.02% 671
2018
Q1
$68M Buy
1,484,099
+56,171
+4% +$2.34M 0.02% 803
2017
Q4
$56.9M Sell
1,427,928
-55,118
-4% -$2.18M 0.02% 935
2017
Q3
$59.3M Sell
1,483,046
-63,283
-4% -$2.74M 0.02% 876
2017
Q2
$66.6M Sell
1,546,329
-122,535
-7% -$4.36M 0.02% 790
2017
Q1
$52.2M Buy
1,668,864
+78,084
+5% +$2.09M 0.01% 933
2016
Q4
$40.2M Sell
1,590,780
-103,246
-6% -$2.31M 0.01% 1071
2016
Q3
$41.9M Buy
1,694,026
+34,422
+2% +$779K 0.01% 989
2016
Q2
$33.8M Buy
1,659,604
+423,835
+34% +$7.52M 0.01% 1083
2016
Q1
$18.8M Buy
1,235,769
+626,875
+103% +$8.18M 0.01% 1446
2015
Q4
$8.18M Buy
608,894
+49,402
+9% +$764K ﹤0.01% 1956
2015
Q3
$7.85M Buy
559,492
+183,300
+49% +$3.41M ﹤0.01% 1988
2015
Q2
$6.39M Buy
376,192
+246,691
+190% +$3.51M ﹤0.01% 2215
2015
Q1
$1.56M Buy
129,501
+1,809
+1% +$17.1K ﹤0.01% 3032
2014
Q4
$1.06M Sell
127,692
-15,916
-11% -$134K ﹤0.01% 3270
2014
Q3
$1.25M Buy
143,608
+18,862
+15% +$170K ﹤0.01% 3165
2014
Q2
$1.37M Buy
124,746
+46,873
+60% +$418K ﹤0.01% 3136
2014
Q1
$696K Buy
77,873
+16,399
+27% +$151K ﹤0.01% 3456
2013
Q4
$463K Buy
61,474
+3,925
+7% +$27.4K ﹤0.01% 3608
2013
Q3
$422K Sell
57,549
-13,871
-19% -$93.2K ﹤0.01% 3579
2013
Q2
$459K Buy
+71,420
New +$421K ﹤0.01% 3532

Other funds holding SUPN

Bank of New York Mellon's SUPN Position: Q2 2026 in Review

Bank of New York Mellon increased its Supernus Pharmaceuticals (SUPN) stake by 4.1% in Q2 2026, buying an estimated $720K and bringing the position to 377,402 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1711.

Bank of New York Mellon first reported a position in SUPN in Q2 2013 and has held it in 53 quarters since. The position peaked at $86.5M in Q2 2018. 162 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Bank of New York Mellon held 377,402 shares of Supernus Pharmaceuticals worth $17.6M as of Q2 2026.
  • Bank of New York Mellon bought 14,994 Supernus Pharmaceuticals shares in Q2 2026, an estimated $720K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1711 holding.
  • Bank of New York Mellon first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's Supernus Pharmaceuticals position peaked at $86.5M in Q2 2018.
  • 162 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.